Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia
Centre Hospitalier Universitaire, Amiens
100 participants
May 14, 2021
INTERVENTIONAL
Conditions
Summary
Walsdenström Macroglobulinemia (WM) is defined by a bone marrow lymphoplasmacytic infiltration and the presence of a monoclonal immunoglobulin M (IgM) in blood. Clinical manifestations of the hyperviscosity syndrome (HVS) are related to the large amount of IgM in circulating blood or to some physicochemical characteristics such as the presence of a cryoglobulin property. Although HVS is one of the most frequent criteria for initiating therapy in WM, few studies focused on its description and no diagnostic criteria are available. The present study aims to identify a diagnostic system for HVS, taking into account objective symptoms such as bleedings, fundoscopic findings and also subjective symptoms such as fatigue and comorbidities that may influence the severity of symptoms.
Eligibility
Inclusion Criteria5
- Patient with WM
- Patients that may require a first-line or subsequent-line therapy
- patients who will require treatment initiation
- patients with serum monoclonal component concentration greater than 15 g/L and who will underwent hyperviscosity assessment, even if hyperviscosity is not found and in the absence of other treatment criteria, no treatment is finally initiated.
- Patients agreeing to give informed consent.
Exclusion Criteria5
- Patients with another chronic B-cell malignancy
- patients with lymphoplasmacytic proliferations
- patients with marginal zone lymphoma.
- patients with WM and histologic transformation
- Absence of informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A central review of numerised fundoscopic picture will be performed.
Two 10 ml blood vials will be sampled in addition to standard blood sampling for getting 6 to 7 200 μL aliquot. One 5 ml EDTA vial for GP1bα expression study, only if this sample can be sent to hemostasis laboratory within the 4 hours after sampling
Five to 10 ml bone marrow sample will be collected in addition to standard bone marrow sampling for getting molecular characteristics of WM
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04898647